Celemics Inc

Celemics Inc exhibits a highly liquid capital structure, with cash and equivalents of 3.21 billion KRW and a current ratio of 6.58, indicating strong short-term liquidity. The company is nearly debt-free, with long-term debt of 376.65 million KRW and a debt-to-equity ratio of 0.02, suggesting minimal leverage risk. However, the company is experiencing negative operating and free cash flows, with operating cash flow of -3.597 billion KRW and free cash flow of -3.482 billion KRW, which may limit its ability to fund growth without external financing. Profitability metrics are negative, with a return on equity of -17.54% and a return on assets of -16.54%, both significantly below the industry median for Biotechnology & Medical Research. The company reported a net loss of 4.036 billion KRW and an operating loss of 3.324 billion KRW, indicating operational challenges. Gross profit of 2.867 billion KRW suggests some margin potential, but the company is not currently translating this into net profitability. The company's revenue is concentrated in disclosed segments, with no specific geographic breakdown provided. However, the company operates in both domestic and overseas markets, indicating some diversification. The lack of detailed segment reporting limits the ability to assess geographic or product-specific performance. Growth trajectory appears mixed. Analysts estimate revenue to increase to 12.1 billion KRW in the next fiscal year, a significant increase from the most recent actual revenue of 5.265 billion KRW. However, the company is expected to continue reporting negative EBIT, with a mean estimate of -200 million KRW, suggesting ongoing profitability challenges. The company's operating income is expected to remain negative, which may impact its ability to scale operations without additional capital. Risk factors include liquidity risk due to negative operating and free cash flows, despite high liquidity in cash reserves. The company has no immediate filing-based liquidity or dilution flags, and dilution risk is assessed as low. However, the need for continued investment in R&D and capital expenditures may require future financing, which could introduce dilution or debt risk. The company's capital expenditure of -165.79 million KRW indicates ongoing investment in infrastructure, which may be necessary for long-term growth. Recent events include the publication of the latest financial snapshot and analyst estimates, which suggest a challenging near-term outlook. The company's negative net income and operating income highlight the need for operational improvements or strategic shifts to achieve profitability. No specific recent filings or transcripts were provided, but the company's financial performance indicates a focus on R&D and market expansion.